Alaunos Therapeutics (TCRT) AI Stock Analysis

• Market Cap: $4.02M
• Dividend Yield: N/A
• Average Volume (3M): 985.96K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.06
• Revenue Growth: 80.00%
• EPS Growth: 86.70%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 73
• Industry: Biotechnology
• EPS (TTM): -2.92
• Shares Outstanding: 1,601,252
• 10 Day Avg. Volume: 2,936,261
• 30 Day Avg. Volume: 985,957
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 397.64
• Price to Cash Flow (P/CF): -0.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Alaunos Therapeutics is in a challenging financial position due to ongoing losses and negative cash flows. While technical indicators suggest positive momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock. The absence of debt provides some financial flexibility, but the need for external funding remains a critical concern.

Alaunos Therapeutics Business Overview & Revenue Model

Company Description

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

How the Company Makes Money

Alaunos Therapeutics generates revenue primarily through the development and commercialization of its TCR-based therapies. The company may earn income through collaboration agreements, research and development partnerships, and potential licensing deals with larger pharmaceutical companies. These partnerships can include milestone payments and royalties based on the successful development and commercialization of therapies. Additionally, Alaunos may seek funding through private and public investments to support ongoing research and clinical trials, although these do not directly constitute revenue.

Alaunos Therapeutics Financial Statement Overview

Summary

Alaunos Therapeutics shows signs of improvement in revenue and cash flow management in the TTM period, but persistent profitability issues and historical volatility in cash flows pose significant risks. The balance sheet remains under pressure due to low equity and ongoing net losses.

Income Statement

The company has experienced significant revenue growth in recent periods, with a TTM revenue increase from previous annual figures. However, it continues to operate at a loss, highlighted by negative gross profit, EBIT, and net income margins, indicating ongoing challenges in achieving profitability.

Balance Sheet

The company's balance sheet shows low leverage with no total debt reported in the TTM period, which is a positive sign. However, the equity ratio has decreased, and the return on equity remains negative due to ongoing net losses, indicating a weak financial position.

Cash Flow

Cash flows have improved with significant positive operating and free cash flows in the TTM period, demonstrating better cash management. However, the historical trend shows volatility, and reliance on financing activities is evident, suggesting potential sustainability concerns.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
6.00K	5.00K	2.92M	398.00K	0.00	0.00
	Gross Profit
-238.00K	-4.80M	163.00K	-342.00K	-1.13M	-629.00K
	EBIT
-7.42M	-34.27M	-35.10M	-77.55M	-80.36M	2.26M
	EBITDA
-11.54M	-30.90M	-31.82M	-74.97M	-78.85M	-117.17M
	Net Income Common Stockholders
-11.78M	-35.14M	-37.60M	-76.89M	-78.85M	-177.92M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
45.04M	6.06M	39.06M	76.05M	115.07M	79.74M
	Total Assets
45.84M	8.26M	64.94M	94.86M	146.34M	109.11M
	Total Debt
0.00	0.00	19.51M	29.36M	4.81M	2.35M
	Net Debt
-45.04M	-6.06M	-19.55M	-46.69M	-110.25M	-77.39M
	Total Liabilities
34.45M	1.96M	26.38M	36.81M	22.36M	109.11M
	Stockholders Equity
11.39M	6.31M	38.55M	58.06M	123.98M	95.01M
Cash Flow		Free Cash Flow
17.91M	-30.34M	-29.45M	-64.79M	-66.79M	-41.14M
	Operating Cash Flow
15.67M	-30.14M	-29.23M	-61.47M	-57.01M	-40.85M
	Investing Cash Flow
1.50M	1.35M	-193.00K	-3.32M	-9.78M	-284.00K
	Financing Cash Flow
-24.95M	-18.14M	6.37M	25.78M	102.12M	59.15M

Alaunos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.67
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCRT, the sentiment is Positive. The current price of 2.67 is above the 20-day moving average (MA) of 2.30, above the 50-day MA of 1.86, and above the 200-day MA of 2.52, indicating a bullish trend. The MACD of 0.31 indicates Negative momentum. The RSI at 55.23 is Neutral, neither overbought nor oversold. The STOCH value of 14.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCRT.

Alaunos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
IOVA	48 Neutral	$1.12B	―	-57.48%	―	13698.99%	31.46%
TCRT	47 Neutral	$4.02M	―	-111.83%	―	80.00%	86.70%
ADAP	46 Neutral	$59.86M	―	-273.36%	―	194.23%	45.50%
CRSP	46 Neutral	$3.34B	―	-19.20%	―	-89.95%	-123.71%
FATE	42 Neutral	$105.93M	―	-54.21%	―	-78.55%	-0.92%
BLUE	36 Underperform	$46.60M	―	-295.35%	―	184.12%	31.92%